Market closed
Repare Therapeutics/RPTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Repare Therapeutics
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
Ticker
RPTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Montreal, Canada
Employees
179
Website
RPTX Metrics
BasicAdvanced
$143M
Market cap
-
P/E ratio
-$1.62
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$143M
Beta
0.72
52-week high
$8.49
52-week low
$2.71
Average daily volume
129K
Financial strength
Current ratio
7.267
Quick ratio
7.083
Long term debt to equity
0.107
Total debt to equity
1.068
Management effectiveness
Return on assets (TTM)
-22.30%
Return on equity (TTM)
-30.52%
Valuation
Price to revenue (TTM)
2.072
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-1.779
Growth
Revenue change (TTM)
-58.79%
Earnings per share change (TTM)
2,110.46%
3-year revenue growth (CAGR)
391.07%
3-year earnings per share growth (CAGR)
-7.92%
What the Analysts think about RPTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Repare Therapeutics stock.
RPTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RPTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RPTX News
AllArticlesVideos
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Business Wire·4 days ago
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Business Wire·2 weeks ago
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Repare Therapeutics stock?
Repare Therapeutics (RPTX) has a market cap of $143M as of October 26, 2024.
What is the P/E ratio for Repare Therapeutics stock?
The price to earnings (P/E) ratio for Repare Therapeutics (RPTX) stock is 0 as of October 26, 2024.
Does Repare Therapeutics stock pay dividends?
No, Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Repare Therapeutics dividend payment date?
Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Repare Therapeutics?
Repare Therapeutics (RPTX) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.